Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 676Neoplasms 590Carcinoma, Non-Small-Cell Lung 285Colorectal Neoplasms 284Prostatic Neoplasms 281Lung Neoplasms 216Melanoma 157Neoplasm Metastasis 145Multiple Myeloma 145Pancreatic Neoplasms 144Head and Neck Neoplasms 142Ovarian Neoplasms 131Carcinoma, Hepatocellular 125Leukemia, Myeloid, Acute 120Brain Neoplasms 113Colonic Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 105Stomach Neoplasms 103Recurrence 100Lymphoma 100Glioblastoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 78Lymphoma, Follicular 78Urinary Bladder Neoplasms 77Hematologic Neoplasms 77Glioma 74Sarcoma 72Parkinson Disease 4, Autosomal Dominant Lewy Body 71

Interventions

MRX-2843 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Processes × 1 year × Clear all
NCT03510104 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Meryx, Inc.

Phase 1 Completed
42 enrolled

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡